Cue Biopharma (CUE) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cue Biopharma (CUE) has outperformed Lyell Immunopharma (LYEL) over the past year, losing 0.4% versus a loss of 51.9%. Over five years, CUE leads with a -92.7% price change compared with -96.7% for LYEL. Lyell Immunopharma is the larger company by market cap ($213.4 million vs $200.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | LYEL |
|---|---|---|
| Share price | $27.66 | $8.71 |
| Market cap | $200.93M | $213.44M |
| 1-day change | +23.87% | -0.91% |
| YTD return | +202.30% | -71.44% |
| 1-year return | -0.43% | -51.86% |
| 5-year return | -92.68% | -96.69% |
| EPS (TTM) | $-29.59 | $-12.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $45.00 |
| 52-week low | $4.98 | $8.21 |
| Distance from 52-week high | -39.21% | -80.64% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +218.15% | +334.90% |
| Average volume | 267.15K | 145.70K |
| Shares outstanding | 7.26M | 24.51M |
| Employees | 29 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed LYEL by 51.4 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
CUE vs LYEL FAQ
Which is bigger, Cue Biopharma or Lyell Immunopharma?
Lyell Immunopharma (LYEL) is larger, with a market capitalization of $213.44M compared with $200.93M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or LYEL?
CUE returned -0.43% over the past 12 months, compared with -51.86% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.